- Home
- SI vs IMRX Comparison
SI vs IMRX Comparison
Compare SI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SI
- IMRX
- Stock Information
- Founded
- SI 2009
- IMRX 2008
- Country
- SI United States
- IMRX United States
- Employees
- SI N/A
- IMRX N/A
- Industry
- SI Medical/Dental Instruments
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- SI Health Care
- IMRX Health Care
- Exchange
- SI Nasdaq
- IMRX Nasdaq
- Market Cap
- SI 248.2M
- IMRX 232.9M
- IPO Year
- SI 2025
- IMRX 2021
- Fundamental
- Price
- SI $13.19
- IMRX $6.17
- Analyst Decision
- SI Strong Buy
- IMRX Strong Buy
- Analyst Count
- SI 5
- IMRX 4
- Target Price
- SI $19.60
- IMRX $17.75
- AVG Volume (30 Days)
- SI 143.6K
- IMRX 3.4M
- Earning Date
- SI 11-10-2025
- IMRX 11-12-2025
- Dividend Yield
- SI N/A
- IMRX N/A
- EPS Growth
- SI N/A
- IMRX N/A
- EPS
- SI N/A
- IMRX N/A
- Revenue
- SI $37,324,000.00
- IMRX N/A
- Revenue This Year
- SI $40.62
- IMRX N/A
- Revenue Next Year
- SI $33.40
- IMRX N/A
- P/E Ratio
- SI N/A
- IMRX N/A
- Revenue Growth
- SI 64.07
- IMRX N/A
- 52 Week Low
- SI $11.51
- IMRX $1.10
- 52 Week High
- SI $17.94
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- SI N/A
- IMRX 46.91
- Support Level
- SI N/A
- IMRX $6.06
- Resistance Level
- SI N/A
- IMRX $9.54
- Average True Range (ATR)
- SI 0.00
- IMRX 0.93
- MACD
- SI 0.00
- IMRX -0.32
- Stochastic Oscillator
- SI 0.00
- IMRX 4.24
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.